{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:44:21Z","timestamp":1793400261249,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"am","delay-in-days":357,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Forensic and Legal Medicine"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jflm.2024.102780","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T20:30:52Z","timestamp":1729369852000},"page":"102780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Xylazine abuse, the growing risk: A review of its effects, upsurge use and associated fatalities in the USA and Puerto Rico"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8618-9518","authenticated-orcid":false,"given":"Luz A.","family":"Silva-Torres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Mozayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jflm.2024.102780_bib1","article-title":"Xylazine and its speedball combination-induction of apoptosis by intrinsic and extrinsic pathway in human umbilical vein endothelial cells","volume":"3","author":"Silva-Torres","year":"2014","journal-title":"J Subst Abuse Alcohol"},{"key":"10.1016\/j.jflm.2024.102780_bib2","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.tiv.2014.06.013","article-title":"Toxic effects of xylazine on endothelial cells in combination with cocaine and 6-monoacetylmorphine","volume":"28","author":"Silva-Torres","year":"2014","journal-title":"Toxicol Vitro"},{"key":"10.1016\/j.jflm.2024.102780_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/492609","article-title":"Xylazine as a drug of abuse and its effects on the generation of reactive species and DNA damage on human umbilical vein endothelial cells","author":"Silva-Torres","year":"2014","journal-title":"J Toxicol"},{"key":"10.1016\/j.jflm.2024.102780_bib4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.drugalcdep.2008.03.005","article-title":"GC-MS confirmation of xylazine (Rompun), a veterinary sedative, in exchanged needles","volume":"96","author":"Rodr\u00edguez","year":"2008","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jflm.2024.102780_bib5","first-page":"6","article-title":"Xylazine (veterinary sedative) use in Puerto Rico","author":"Torruella","year":"2011","journal-title":"Subst Abuse Treat Prev Pol"},{"key":"10.1016\/j.jflm.2024.102780_bib6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12954-024-00978-z","article-title":"A confirmed case of xylazine-induced skin ulcers in a person who injects drugs in Miami, Florida, USA","volume":"21","author":"Warp","year":"2024","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.jflm.2024.102780_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2344\/0003-3006-62.1.31","article-title":"Alpha-2 adrenergic receptor agonists: a review of current clinical applications","volume":"62","author":"Giovannitti","year":"2015","journal-title":"Anesth Prog"},{"key":"10.1016\/j.jflm.2024.102780_bib8","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.36864","article-title":"Xylazine in the opioid epidemic: a systematic review of case reports and clinical implications","author":"Ayub","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jflm.2024.102780_bib9","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.28160","article-title":"Xylazine-induced skin ulcers in a person who injects drugs in Philadelphia, Pennsylvania, USA","author":"Malayala","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.jflm.2024.102780_bib10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11524-011-9662-6","article-title":"The emerging of xylazine as a new drug of abuse and its health consequences among drug users in Puerto Rico","volume":"89","author":"Reyes","year":"2012","journal-title":"J Urban Health"},{"key":"10.1016\/j.jflm.2024.102780_bib12","article-title":"Injection of Xylazine mixed with heroin associated with poor health outcomes and HIV risk behaviors in Puerto Rico","volume":"S1","author":"L\u00f3pez","year":"2015","journal-title":"Addiction Sci Clin Pract"},{"key":"10.1016\/j.jflm.2024.102780_bib13","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/injuryprev-2020-043968","article-title":"Increasing presence of xylazine in heroin and\/or fentanyl deaths, Philadelphia, Pennsylvania, 2010-2019","volume":"4","author":"Johnson","year":"2021","journal-title":"Inj Prev"},{"key":"10.1016\/j.jflm.2024.102780_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109644","article-title":"Correlates of recent overdose among people who inject drugs in the San Diego\/Tijuana border region","volume":"240","author":"Bailey","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jflm.2024.102780_bib15","article-title":"Xylazine in drug seizure reports and overdose deaths in the U.S. 2018-2022","author":"Cano","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jflm.2024.102780_bib16","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.15585\/mmwr.mm7037a4","article-title":"Notes from the field: xylazine detection and involvement in drug overdose deaths \u2014 United States","volume":"70","author":"Kariisa","year":"2019","journal-title":"Morbid Morta Weekly Rep"},{"issue":"6","key":"10.1016\/j.jflm.2024.102780_bib17","article-title":"Xylazine-involved fatal and nonfatal drug overdoses in Tennessee from 2019 to 2022","author":"Korona-Bailey","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jflm.2024.102780_bib18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12954-021-00546-9","article-title":"Xylazine detected in unregulated opioids and drug administration equipment in Toronto, Canada: clinical and social implications","volume":"189","author":"Bowles","year":"2021","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.jflm.2024.102780_bib19","first-page":"17","article-title":"Evaluating networked drug checking services in Toronto, Ontario: study protocol and rationale","volume":"10","author":"Maghsoudi","year":"2020","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.jflm.2024.102780_bib20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2885.1988.tb00189.x","article-title":"Xylazine \u2013 a review of its pharmacology and use in veterinary medicine","volume":"11","author":"Greene","year":"1988","journal-title":"J Vet Pharmacol Therapeut"},{"key":"10.1016\/j.jflm.2024.102780_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/PAF.0000000000000622","article-title":"A veterinary tranquilizer, detected in 42 accidental fentanyl intoxication deaths","author":"Nunez","year":"2021","journal-title":"Am J Forensic Med Pathol"},{"key":"10.1016\/j.jflm.2024.102780_bib22","first-page":"2","article-title":"DEA joint intelligence report the growing threat of xylazine and its mixture with illicit drugs","year":"2022","journal-title":"Growing Threa Xylazine Mixt Illicit Drugs"},{"key":"10.1016\/j.jflm.2024.102780_bib23","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/ADM.0000000000000955","article-title":"Management of xylazine withdrawal in a hospitalized patient: a case report","volume":"16","author":"Ehrman-Dupre","year":"2022","journal-title":"J Addiction Med"},{"key":"10.1016\/j.jflm.2024.102780_bib24","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/jat\/bkac049","article-title":"Pharmacology review and prevalence and drug combinations in forensic toxicology casework","volume":"46","author":"Kacinko","year":"2022","journal-title":"J Anal Toxicol"},{"key":"10.1016\/j.jflm.2024.102780_bib25","article-title":"Xylazine spreads across the U.S.: a growing component of the increasingly synthetic and polysubstance overdose crisis","volume":"10","author":"Friedman","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.jflm.2024.102780_bib26","first-page":"229","article-title":"The role of xylazine in the overdose crisis","volume":"108","author":"Vega","year":"2023","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jflm.2024.102780_bib27","unstructured":"Baker, N. J., Schofield, J. C., Caswell, M. D., & Mclellan, A. D. Effects of early atipamezole reversal of medetomidine-ketamine anesthesia in mice. In JAALAS. 201;50:6."},{"key":"10.1016\/j.jflm.2024.102780_bib28","article-title":"A protocol for the emergency treatment of alpha-2 agonist overdose using atipamezole, a selective alpha-2 antagonist","volume":"12","author":"Greenberg","year":"2017","journal-title":"Internet J Toxicol"},{"key":"10.1016\/j.jflm.2024.102780_bib29","first-page":"29","article-title":"Pharmacological profiles of medetomidine and its antagonist, atipamezole","volume":"85","author":"Elliott","year":"1989","journal-title":"Acta Vet Scand Suppl"},{"key":"10.1016\/j.jflm.2024.102780_bib30","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1177\/026988119100500434","article-title":"Acute and chronic idazoxan in normal volunteers: biochemical, physiological and psychological effects","volume":"5","author":"Glue","year":"1991","journal-title":"J Psychopharmacol"},{"issue":"8","key":"10.1016\/j.jflm.2024.102780_bib31","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2105\/AJPH.2022.306881","article-title":"Xylazine and overdoses: trends, concerns, and recommendations","volume":"112","author":"Alexander","year":"2022","journal-title":"Am J Publ Health"},{"key":"10.1016\/j.jflm.2024.102780_bib32","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/acer.12658","article-title":"Effects of idazoxan on alcohol pharmacokinetics and intoxication: a preliminary human laboratory study","volume":"39","author":"Haass-Koffler","year":"2015","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"10.1016\/j.jflm.2024.102780_bib33","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/clpt.1984.161","article-title":"The alpha-adrenoceptor antagonist properties of idazoxan in normal subjects","volume":"36","author":"Reid","year":"1984","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.jflm.2024.102780_bib34","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/BF00615972","article-title":"The pharmacokinetics after intravenous and oral administration in man of the \u03b12-adrenoreceptor antagonist idazoxan (RX781094)","volume":"29","author":"Muir","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jflm.2024.102780_bib36","doi-asserted-by":"crossref","first-page":"760","DOI":"10.5498\/wjp.v14.i6.760","article-title":"Fentanyl and xylazine crisis: crafting coherent strategies for opioid overdose prevention","volume":"14","author":"Jain","year":"2024","journal-title":"World J Psychiatr"}],"container-title":["Journal of Forensic and Legal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1752928X24001422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1752928X24001422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T10:03:18Z","timestamp":1732960998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1752928X24001422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":34,"alternative-id":["S1752928X24001422"],"URL":"https:\/\/doi.org\/10.1016\/j.jflm.2024.102780","relation":{},"ISSN":["1752-928X"],"issn-type":[{"value":"1752-928X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Xylazine abuse, the growing risk: A review of its effects, upsurge use and associated fatalities in the USA and Puerto Rico","name":"articletitle","label":"Article Title"},{"value":"Journal of Forensic and Legal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jflm.2024.102780","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd and Faculty of Forensic and Legal Medicine. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102780"}}